The evolving role of radiotherapy in treatment of oligometastatic NSCLC.

Published

Journal Article (Review)

Non-small cell lung cancer (NSCLC) patients with metastases limited in site and number, termed oligometastases, may represent a unique subpopulation of advanced NSCLC with improved prognosis. The optimal management of these patients remains unclear with the treatment approach currently undergoing a paradigm shift. The potential benefit of aggressive metastasis directed local treatment with surgery and/or radiotherapy (RT) in combination with systemic therapy is bolstered predominantly by retrospective analyses but also by a growing number of non-randomized prospective studies regarding the use of ablative RT techniques including stereotactic body radiotherapy (SBRT), alternatively termed stereotactic ablative radiotherapy (SABR), directed at the primary tumor (if present) and all metastatic sites. Long-term survival is possible in a subset of patients treated aggressively in this manner. The challenge for the clinical oncology community moving forward is appropriately selecting patients for this treatment approach based on clinical, imaging, and molecular features and increasing enrollment of patients to prospective clinical trials to more definitively determine the added benefit and appropriate timing of aggressive metastasis directed therapy in the oligometastatic setting.

Full Text

Duke Authors

Cited Authors

  • Bergsma, DP; Salama, JK; Singh, DP; Chmura, SJ; Milano, MT

Published Date

  • 2015

Published In

Volume / Issue

  • 15 / 12

Start / End Page

  • 1459 - 1471

PubMed ID

  • 26536370

Pubmed Central ID

  • 26536370

Electronic International Standard Serial Number (EISSN)

  • 1744-8328

Digital Object Identifier (DOI)

  • 10.1586/14737140.2015.1105745

Language

  • eng

Conference Location

  • England